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Background: Our recent study showed the global physiological function of the differentially expressed genes of
prostate cancer in Chinese patients was different from that of other non-Chinese populations. microRNA are
estimated to regulate the expression of greater than 60% of all protein-coding genes. To further investigate the
global association between the transcript abundance of miRNAs and their target mRNAs in Chinese patients, we
used microRNA microarray approach combined with bioinformatics and clinical-pathological assay to investigate
the miRNA profile and evaluate the potential of miRNAs as diagnostic and prognostic markers in Chinese patients.
Results: A total of 28 miRNAs (fold change ≥1.5; P≤ 0.05) were differentially expressed between tumor tissue and
adjacent benign tissue of 4 prostate cancer patients.10 top Differentially expressed miRNAs were validated by
qRT-PCR using all 20 tissue pairs. Compared to the miRNA profile of non-Chinese populations, the current study
showed that miR-23b, miR-220, miR-221, miR-222, and miR-205 maybe common critical therapeutic targets in
different populations. The integrated analysis for mRNA microarray and miRNA microarray showed the effects of
specifically inhibiting and/or enhancing the function of miRNAs on the gene transcription level. The current studies
also identified 15 specific expressed miRNAs in Chinese patients. The clinical feature statistics revealed that
miR-374b and miR-19a have significant correlations with clinical-pathological features in Chinese patients.
Conclusions: Our findings showed Chinese prostate cancer patients have a common and specific miRNA
expression profile compared with non-Chinese populations. The miR-374b is down-regulated in prostate cancer
tissue, and it can be identified as an independent predictor of biochemical recurrence-free survival.
Keywords: Prostate cancer, miRNA expression profile, miR-374b, mRNA expression profileBackground
MicroRNAs (miRNAs) are small non-coding RNA mole-
cules of 21-23nt that have deregulated expression in hu-
man cancer tissue [1]. Their deregulation has been
shown to play a vital role in cancer initiation, progres-
sion and metastasis [2] and miRNAs represent a promis-
ing new class of cancer biomarker [3,4]. Recent studies
demonstrate that miRNA expression patterns serve as
phenotypic signatures of different cancers and could be
used as diagnostic, prognostic and therapeutic tools [5].* Correspondence: xingyinliu@hotmail.com; zhongwd2009@live.cn
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reproduction in any medium, provided the orProstate cancer is the most common cancer in men in
western countries [6]. A few studies have analyzed global
microRNA expression profiles or the functional role of
microRNAs in prostate cancer [7,8]. However the results
showed highly inconsistent [8].
Prostate cancer occurrence in the Chinese popula-
tions was lower than that of the western countries. Our
recent study showed the global physiological function of
the differentially expressed genes of prostate cancer in
Chinese patients was different from that of other non-
Chinese populations [9], which suggest that the deregu-
lation of cell cycle progression maybe a “key” to differ-
entiate the epidemiological differences between Chinese
and non-Chinese. On the one hand, miRNAs are esti-
mated to regulate the expression of greater than 60% of
all protein-coding genes [10]. On the other hand, accu-
mulating evidence suggests that miRNAs can contributeThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or tumor suppressor pathways [4]. So it should be kept in
mind that there are genetic characteristics of prostate can-
cer patients from different populations. In the last few
years, increasing evidence has documented the role of
microRNAs as new broad-spectrum oncogenes or tumor
suppressor genes, thus their use as diagnostic, prognostic
and therapeutic biomolecules is envisaged [11]. So more in-
vestigation on the expression profiles of miRNAs is needed
to understand of the role of miRNAs in the development
and progression of prostate cancer in different populations.
Recent studies have shown that microRNA inhibitory
activity can be quantified by examining their target mRNA
expression levels [12]. Therefore, in order to functionally
investigated differentially expressed miRNAs targets, all of
patients samples in this study are same as previous report
about mRNA transcript study [9]. The objective of this
study was to evaluate the potential of miRNAs as diagnos-
tic and/or prognostic markers and to further provide a
solid data basis for further functional analyses of prostate
cancer-relevant miRNAs in Chinese patients.
Method
Patients and sample collection
Prostate tissues were obtained from the tissue bank at
Guangzhou Medical University. All patients who partici-
pated in the study had given informed consent. The col-
lection of the tissue specimens in accordance with the
protocol was approved by the Institutional Ethical Board
of Guangzhou Medical University. The clinic pathological
data of these patients are summarized in Additional file 1:
Table S1. The frozen tissues were procured immediately
after surgery, cut into the size of ~1 cm2 × 0.5 cm pieces,
fast-frozen in liquid nitrogen and stored at −80°C.
Sample LCM and RNA preparation
The whole sample treatment and RNA extraction
process were previously described by Chen JH et al. [9].
miRNA expression microarray
Microarray experiments were carried out using 1-color
hybridizations on human miRNA Microarray (V3, 8x15K)
(Agilent, Cat No.:G4471A-021827), One glass slide for-
matted with eight high-definition 15 K arrays, based on
Sanger miRbase (release 12.0), Probes: 866 human and 89
human viral miRNAs represented. The miRNA expres-
sions data are available at GEO (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE34932), which included a
total of 16 samples data.
Microarray data analysis
The microarray image information was converted into spot
intensity values using Scanner Control Software Rev. 7.0
(Agilent). The signal after background subtraction wasexported directly into the GeneSpring GX11 software
(Agilent) for normalization. The mean normalized signal
from biological replicates was used for comparative expres-
sion analysis. Paired t-test with Benjamini-Hochberg cor-
rection (P value ≤ 0.05) was used to identify differentially
expressed miRNAs between tumor and benign tissues. The
fold changes of expression signals between tumor and be-
nign samples were calculated from the normalized values.
Hierarchical clustering was performed with Pearson correl-
ation using the differentially expressed miRNAs. 4 pairs
cancer and benign tissues data (C2,C3,C4,C5,N2,N3,N4,
N5) were used for further analysis.
Confirmation of miRNA expression
For miRNA detection, qRT-PCR was processing as the
protocol of All-in-One™ miRNA qRT-PCR Detection Kit
(Cat No.:AOMD-Q020, GeneCopoeia, China) described. All
assays were carried out in triplicate. miRNA expression in
each sample was normalized with the house keeping gene
(RNU6B and hsa-miR-130b) expression. The specificity of
amplification was confirmed by melting curve analysis and
also by running PCR products on agarose gels (3%). Rela-
tive quantification of target miRNA expression was evalu-
ated using the comparative cycle threshold (CT) method.
MiRCURY LNA™ Detection probes 5′-DIG labeled (Cat
No.:18091–01 for miR-19a, 38748–01 for miR-374b,
99002-01 for U6, Exiqon, Denmark) were used to detect
the in situ hybridization signal for target miRNA on
formalin-fixed or frozen section of prostate tissues. In situ
hybridization was performed according to the manufac-
turer’s instructions of Enhanced sensitivity of in situ
hybridization detection kit (peroxidase) (Cat No.: MK1030,
Boster, China). The result scoring of in situ hybridization
experiment was detail described by He HC et al. [13].
Target gene prediction and integrated analysis by IPA
The selected miRNAs were further analyzed to identify
the networks and pathways targets. Target prediction
using TargetScan, combined with bioinformatics analysis
(Ingenuity Pathway Analysis, IPA). The identified targets
were compared with mRNA microarray (GEO Accession
No: GSE28204) from the same patients to evaluate the
implications of the altered miRNA expression [9].
Statistical analysis
Data comparing differences in levels of expression of miR-
NAs between tumor tissue and adjacent benign tissue
were analyzed using paired Student’s t-test by the software
of Genespring version GX 11 (Agilent Inc, USA). Other
data were statistically analyzed by the software of SPSS
version13.0 for Windows (SPSS Inc, USA). Continuous
variables were expressed as X  s , paired Student’s t-test
for qRT-PCR data, independent t-test for in situ
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ical recurrence free-survival, and Cox regression model
for the univariate and multivariate analysis. Differences
were considered statistically significant when P < 0.05.
Results
miRNA expression profiling of clinical samples
In this study, total RNA from 4 pairs of primary cancer
tissue and the adjacent benign tissue of prostate gland
were labelled and hybridized to miRNA microarray chip
containing probes of 866 human and 89 human viral miR-
NAs represented. A total of 28 miRNAs (Fold time ≥1.5;
P ≤ 0.05) were differentially expressed between tumor
tissue and adjacent benign tissue of 4 prostate cancer
patients. Figure 1 shows the results of the two-way hier-
archical clustering of miRNAs. Each row represents a
miRNA, and each column is a sample of either tumor
tissues (C2, C3, C4, C5) or benign tissues (N2,N3, N4,Figure 1 Heat map diagram and hierarchical clustering of
differentially expression miRNAs between matched tumor and
adjacent benign tissue. Each row represents a miRNA, and each
column a sample either tumor tissue (C2, C3, C4, C5 and C6) or
benign tissue (N2, N3, N4 and N5). The color scale shown at the
bottom illustrates the relative expression level of a miRNA across
all samples.N5). The colour scale shown at the bottom left illus-
trates the relative expression level of a miRNA across all
samples. Of these 28 miRNAs genes, 11 miRNAs (39%)
were up-regulated and 17 miRNAS (61%) were down-
regulated respectively. Of the 11 miRNAs that were up-
regulated in the tumor tissue, 8 miRNAs had a fold
change more than two fold times. Of the 17 down-
regulated miRNAs, 14 miRNAs had a fold change of
more than two fold times. Additionally, miR-205
showed huge down-regulated in the tumor tissue with a
fold change of greater than 50 times. Genomic locations
and properties of the differentially expressed miRNAs
are shown in Table 1.
Validation of differentially expressed miRNA by qRT-PCR
analysis
To validate the array results in miRNA, we selected 5
down-regulated miRNAs in tumor tissue, (miR-205,miR-
221, miR-155, miR-455-3P, and miR-193a-5p) and 5 up-
regulated miRNAs (miR-1224-5p, miR-939, miR-188-5p,
miR-1249, and miR-663) (miR-1225-5p and hcmv-miR-
UL70-3p were exclude for lacking the primer for qRT-
PCR) to do real-time PCR in tumor tissues and paired
adjacent benign tissues (n = 20). As shown in Figure 2A,
all of the 5 down-regulated miRNAs showed a signifi-
cant differential expression measured by a paired t-test;
in the up-regulated miRNAs group, however, although
the real-time PCR results of miR-1224-5p, miR-1249,
and miR-663 were consistent with the microarray data,
miR-939 and miR-188-5P had no significant differential
expression (P> 0.1).
Functional analysis of differentially expressed miRNA by
global and integrated analysis of the miRNA and mRNA
expression profile
To further investigate the global association between the
transcript abundance of miRNAs and their target
mRNAs in prostate cancer, we used IPA pathway ana-
lysis software to perform target predication and func-
tional analysis of the 21 differentially expressed miRNAs
(fold change ≥ 2, P< 0.05, virus miRNAs were excluded).
As shown in Figure 3, 18 differentially expressed miR-
NAs formed a regulated network that combined their re-
lated genes. The network was correlated with the
following functions: reproductive system disease, cancer,
and endocrine system disorders. We further compared
the predicted targets of 21 miRNAs to the differentially
expressed mRNA level data (GSE NO.GSE28204, mRNA
fold change ≥ 1.5, P< 0.05) from the same samples. Even
though there were many potential target genes predicted
for the screened miRNAs, the integrated analysis mRNA
and miRNA expression profile enabled us to generate an
experimental target list consisting of 204 potential genes
from all the predicted targets (Additional file 2: Table S2).
Table 1 The differentially expressed miRNAs in PCa (Fold change ≥ 1.5, P< 0.05)
Systematic name miRNA microarray data Chromosomal location
Regulation Fold change P
hsa-miR-205 down 58.96 0.009 1:209605478-209605587[+]
hsa-miR-221 down 5.15 0.036 X:45605585-45605694[−]
hsa-miR-155 down 4.83 0.021 21:26946292-26946356[+]
hsa-miR-455-3p down 4.39 0.014 9:116971714-116971809[+]
hsa-miR-193a-5p down 4.31 0.001 17:29887015-29887102[+]
hsa-miR-222 down 3.94 0.036 X:45606421-45606530[−]
hsa-miR-221-5p down 3.50 0.050 X:45605585-45605694[−]
hsa-miR-200b-5p down 3.44 0.014 1:1102484-1102578[+]
hsa-miR-335 down 3.36 0.015 7:130135952-130136045[+]
hsa-miR-224 down 3.32 0.011 X:151127050-151127130[−]
hsa-miR-505 down 2.72 0.038 X:139006307-139006390[−]
hsa-miR-23b down 2.70 0.033 9:97847490-97847586[+]
hsa-miR-374b down 2.11 0.013 X:73438382-73438453[−]
hsa-miR-30c down 2.09 0.018 1:41222956-41223044[+]
hsa-miR-26b down 1.93 0.016 2:219267369-219267445[+]
hsa-miR-181d down 1.70 0.031 19:13985689-13985825[+]
hsa-miR-374a down 1.61 0.043 X:73507121-73507192[−]
hcmv-miR-UL70-3p up 6.36 0.008
hsa-miR-1224-5p up 3.72 0.028 3:183959193-183959277[+]
hsa-miR-939 up 3.67 0.030 8:145619364-145619445[−]
hsa-miR-1225-5p up 3.37 0.041 16:2140196-2140285[−]
hsa-miR-188-5p up 3.27 0.034 X:49768109-49768194[+]
hsa-miR-1249 up 2.75 0.008 22:45596835-45596900[−]
hsa-miR-663 up 2.71 0.044 20:26188822-26188914[−]
hsa-miR-574-5p up 2.38 0.043 4:38869653-38869748[+]
hsa-miR-19a up 1.83 0.038 13:92003145-92003226[+]
kshv-miR-K12-3 up 1.80 0.009
hsa-miR-1915 up 1.50 0.013 10:21785491-21785570[−]
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that were potentially targeted by either up-regulated or
down-regulated miRNAs. The group showing up-
regulated mRNAs associated only with down-regulated
miRNAs consisted of 168 mRNAs; the group showing
down-regulated mRNAs associated only with up-
regulated miRNAs consisted of 36 mRNAs. From this
screened target set, we found that miR-155, miR-19a,
miR-205a, miR-221, and miR-374b had the highest
number targets (see Additional file 2: Table S2). To
identify putative targets and to provide a foundation for
functional analyses, we performed IPA function and
pathway analysis for their targets. The screened miRNAs
target genes were found to be associated with cell morph-
ology, cell death, cellular development, cellular growth
and proliferation, cellular assembly and organization, cel-
lular function and maintenance, cellular movement, cell-to-cell signaling and interaction, gene expression, cell
cycle, and so on (Figure 4A, Additional file 3: Table S3).
To further elucidate the specific functions of these
genes, a detailed pathway analysis was performed using
ingenuity pathway analysis for all target sets (Figure 4B,
Additional file 4: Table S4). The top 10 pathways were
the following: Agrin Interactions at Neuromuscular
Junction, PTEN Signaling, p53 Signaling, Oncostatin M
Signaling, Cell Cycle: G1/S Checkpoint Regulation,
CDK5 Signaling, Polyamine Regulation in Colon
Cancer, Paxillin Signaling, Estrogen-Mediated S-phase
Entry, and NF-κB Activation by Viruses.
Common and specific features of miRNA expression
profile in PCa tissues from Chinese patients
On the basis of these microarray experiments, we com-
pared our data with other microarray data regarding
Figure 2 Real-time PCR validation of microarray result. Selected miRNAs were measured by real-time PCR in tumor tissues and paired
adjacent benign tissues (n = 20). Horizontal bars represent the mean. P vlaues were measured by paired t-test. (A) real-time PCR analysis for
up-regulated miRNAs in microarray result. (B) real-time PCR analysis for down-regulated miRNAs in microarray result.
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accession numbers for Taylor data, Schaefer data, and
Lin data are GSE21036, GSE14857, and GSE36802, re-
spectively). 13 differentially expressed miRNAs of ourmicroarray data—miR-23b, miR-30c, miR-221, miR-221-
5p, miR-222, miR-224, miR-205, miR-455-3p, miR-505,
miR-663, miR-1224-5p, miR-1225-5p and hcmv-miR-
UL70-3p—showed the same expression pattern as that
Figure 3 Ingenuity pathway network analysis of differentially expressed miRNAs. Depicting relationships among differentially expressed
miRNAs in prostate cancer tissue compared with adjacent benign tissue (fold change≥ 2, P< 0.05, virus miRNAs were excluded). Intensity of the
red color indicates the degree of up-regulation. Intensity of the green color indicates the degree of down-regulation. Nodes are displayed using
various shapes that represent the functional class of the gene product. Edges are displayed with various labels that describe the nature of
relationship between the nodes: ___ represents direct relationship; –——— represents indirect relationship;→represents acts on.
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these miRNAs, miR-205 was the most down-regulated
miRNA both in our data and other 3 GEO data. Thus,
our data reflect the shared feature of the miRNA expres-
sion profile in PCa tissues. Nevertheless, after conduct-
ing an additional literature search(Additional file 5:
Table S5), we identified 15 differentially expressed miR-
NAs (miR-19a, miR-26b, miR-155, miR-181d, miR-188-
5p, miR-193a-5p, miR-200b-5p, miR-335, miR-374a,
miR-374b, miR-574-5p, miR-939, miR-1249, miR-1915,
kshv-miR-K123) that have not been reported in Western
PCa patients. Given the confirmed result of the qRT-
PCR, miR-188-5p, miR-19a, miR-193a-5p, and miR-374b
were chosen to further study the association of miRNA
expression with the clinical-pathological features of PCa
patients.
Using in situ hybridization to analyze the expression level
of the chosen miRNAs in 104 PCa tissues and 25 adjacent
benign prostate tissues, we found that the miR-19a showed
up-regulated expression (staining score: PCa = 4.83 ± 0.76
vs. Benign = 4.15 ± 0.55, P= 0.004, Figure 5A–B). Con-
versely, the expression levels of miRNA-374b and miR-
193a-5p in PCa tissues were significantly lower than thosein adjacent benign prostate tissues (miRNA-374b staining
score: PCa = 3.97 ± 1.17 vs. Benign = 4.70 ± 0.71, P = 0.032,
Figure 5C–D; miR-193a-5p staining score: PCa = 3.21 ± 0.60
vs. Benign = 3.60 ± 0.55, P= 0.003). However, miR-188-5p
showed no significant expression (data not shown, staining
score: PCa = 3.49 ± 1.18 vs. Benign = 3.16 ± 0.78, P= 0.09).
Figure 5 shows the representative images of miRNA-374b
and miR-19a expression through in situ hybridization.
The clinical feature statistics revealed that only miR-
374b and miR-19a had significant correlation with clin-
ical features of prostate patients (Table 2). The reduced
expression of miR-374b was frequently found in PCa tis-
sues with a Gleason score (P = 0.003), pathological stage
(P = 0.039), metastasis (P = 0.001), overall survival (P =
0.020), and PSA failure status (P = 0.002), whereas the
up-regulation of miR-19a was only associated with high
serum PSA levels (P = 0.020).
The associations of the expression levels of miR-19a
and miR-374b with the biochemical recurrence-free sur-
vival and the overall survival of PCa patients were ana-
lyzed using the Kaplan–Meier method (Figure 6). The
data indicated that the biochemical recurrence-free sur-
vival of patients with higher miR-374b expression was
Figure 4 Function and pathway analysis identified by IPA associated with targets genes. Functional analysis for targets genes, which got
from by combining the predicted target gene result by IPA software for differentially expressed miRNAs (fold change≥ 2, P< 0.05) with the mRNA
expression profile result (GSE NO.GSE28204, mRNA fold change≥ 1.5, P< 0.05). (A): The 10 most significant function directory across the entire
dataset, and across multiple datasets, y-axis displays the significance. For the ratio, taller bars have more genes associated with the canonical
pathway than shorter bars. (B) The 10 most significant canonical pathways across the entire dataset, and across multiple datasets, y-axis displays
the significance. For the ratio, taller bars have more genes associated with the canonical pathway than shorter bars.
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374b expression (P = 0.005). Furthermore, the multivari-
ate analyses showed that the down-regulation of miR-
374b (P = 0.018) and a higher Gleason score (P = 0.003)
were both independent predictors of shorter biochemical
recurrence-free survival (Table 3).
To determine whether miR-374b may modulate
mRNA levels in prostate cancer patients, we compared
the targets genes with our microarray expression data-
base from our previous study [9] to determine whether
any of the potential targets were significantly up-
regulated in tumor tissue. We predicted that there would
be decreased degradation due to loss of the miRNAtargeting them. As shown in Additional file 2: Table S2,
a total of 34 genes that were predicted miR-374b target
genes were significantly increased in prostate cancer.
IPA pathway analysis showed that some of these genes
had a significant impact on the biological and clinical
behavior of prostate cancer (Figure 7).
Discussion
In this study,we elaborated on the miRNA expression
profile by using microarray in 4 matched pairs of histo-
logically confirmed tumor tissue and adjacent benign tis-
sue. Remarkably, 28 of the miRNAs showed differential
expression. Some miRNAs were subsequently validated
Figure 5 The representative in situ hybridization images of miRNA-374b and miR-19a. The miR-19a in-situ hybridization images in benign
tissue (A) and cancer tissue (B); The miR-394b in-situ hybridization images in benign tissue (C) and cancer tissue (D); (E) is the positive control U6
RNA in-situ hybridization images and (F) is the blank control by replacing the RNA probe with PBS solution.
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miRNAs were of special interest because of their
putative targets. Because putative target genes for differ-
entially expressed miRNAs are a first step in understan-
ding miRNAs with potential significance in the process
of tumor development, we identified putative target
genes for each of the differentially expressed miRNAs
using IPA software. To provide a foundation for our
functional analyses, we performed an integrated analysis
for our previous mRNA microarray database and IPA-
predicted miRNA target analysis (Additional file 2: Table
S2). miR-205 has been reported to be down-regulated in
prostate cancer patients and has been shown to be onco-
genic [14-17]. Recently, Gandellini et al. [17] reported
that miR-205 is essential for maintenance of the base
membrane (BM) in prostate epithelium and pointed out
that miR-205 may favour tumorigenesis by creating dis-
continuities in the BM. Actually, the network analysis
showed centre localization of miR-205 (Figure 3), and
IPA analysis for predicting targets of miR-205 showedthat these targets play a role in regulating tumor morph-
ology, which suggests that miR-205 maybe involved in
prostate cancer progression. E2F1 as miR-205 target was
observed in this network, interestingly, E2F1 is one of the
most frequently observed potential markers for discrimin-
ating benign and malignant disease [18]. When comparing
these targets shown in the network to our previous mRNA
microarray data [9], however, we found that only TLK tar-
geted by miR-205 showed significant up-regulation. Ron-
ald et al. [19] reported that TLK expressed in a panel of
PCa cell lines and their related to radioresistance. Further-
more, the expression of TLK1B in non-expressing PC-3
cells rendered them highly resistant to radiation; con-
versely, a knockdown to TLK1/1B in expressing DU145
reduced their radio tolerance. TLKs appear to be intim-
ately linked to the pattern of resistance to DNA damage,
and specifically to double-strand break(DSB) repair.
Hence, our microarray data confirms the possibility of ex-
tending the downstream signaling of miR-205 involved in
the DNA repair process.
Table 2 Association of miRNA expression with the clinic-pathological features of PCa patients
Clinical features Case no. miR-19a miR-374b
P P
Age (years)
<60 67 4.87 ± 0.62 0.43 3.81 ± 1.19 0.23
≥60 37 4.75 ± 0.97 4.08 ± 1.05
Serum PSA levels (ng/ml)#
<10 21 4.80 ± 0.66 0.020* 4.00 ± 0.81 0.98
≥10 82 5.16 ± 0.44 4.00 ± 1.17
Gleason score#
<8 81 4.91 ± 0.44 0.16 3.01 ± 1.571 0.003**
≥8 18 4.68 ± 1.11 4.28 ± 0.692
Clinical stage#
<T2A 59 4.76 ± 0.65 0.11 3.94 ± 0.146 0.21
≥T2A 41 4.96 ± 0.55 4.21 ± 0.856
Pathological stage#
T2A-T2C 65 4.82 ± 0.52 0.46 3.64 ± 1.480 0.039*
T3A-T4 35 4.91 ± 0.80 4.21 ± 0.775
Metastasis#
No 86 4.89 ± 0.49 0.11 4.25 ± 0.076 0.001**
Yes 18 4.57 ± 1.50 2.70 ± 1.661
Overall survival
Alived 94 4.91 ± 0.55 0.13 4.13 ± 0.096 0.020*
Dead 10 4.04 ± 1.66 2.65 ± 1.655
PSA failure#
Negative 72 4.88 ± 0.45 0.90 4.31 ± 0.081 0.002**
Positive 27 4.86 ± 0.90 3.36 ± 1.419
#Some patients had missing data for some clinical feature.
* P < 0.05, ** P < 0.01.
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frequently observed in prostate cancer samples [8,20,21].
Our analysis is in concordance with these prior studies of
prostate cancer. IPA analysis for targets of miR-221/222
showed that these targets play a role in regulating tumor
morphology. Interestingly, some of the differentially
expressed genes targeted by miR-221 and miR-222 have
previously been associated with prostate cancer in Western
patients, such as Ttspan13, which is overexpressed in pros-
tate cancer and whose expression correlates with factors of
favourable outcomes [22]. Among the candidates, CDON
encodes the CDO protein, an orphan cell surface receptor
from the immunoglobulin superfamily. Additional quanti-
tative RT-PCR revealed that 83% of PCa tissues showed
CDON overexpression. Knockdown of CDON in DU145
cells induced 5-fluorouracil-induced apoptosis and inhib-
ited invasion ability. Therefore, CDON was suggested, as it
has a high potential as a therapeutic target for PCa [23].
A down-regulated expression level of miR-23b was
found in malignant tissues of prostate cancer [21].Ectopic expression of these miRNAs significantly re-
duced LNCaP cancer cell growth, suggesting growth-
modulatory roles for miR-23b. Majidand and his
colleagues [24] reported that miR-23b expression caused
a dramatic decrease in tumor growth in nude mice and
attenuated Src expression. Also, the increased expression
of miR-23b inhibited proliferation, colony formation,
and migration/invasion and triggered G0/G1 cell cycle
arrest and apoptosis in PCa [24]. As such, these findings
suggest that re-expression of miR-23b may contribute to
the epigenetic therapy for PCa. In our recent study [13],
we also identified miR-23b as a candidate miRNA that
targets PRDX3. The expression levels of miR-23b and
PRDX3 in PCa tissues were found to be related to the
severity of the tumor malignancy, suggesting their clin-
ical relevance. The integrated miRNA target analysis
showed that most of the targets for miR-23b are known
to be involved in cellular assembly and the cell cycle.
Based on the above information, we speculate that the
activity of miR-23b may be conserved in Western and
Figure 6 Kaplan-Meier survival curves of biochemical recurrence-free (A and C) and overall survival (B and D) for miRNA-19a and
miR-374b expression in patients with prostate cancer.
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analysis extends the downstream signaling of their stud-
ies and provides more comprehensive information about
miR-23b in tumor growth.
In a number of studies, miRNAs such as let-7 family
[25], miR-148 [26,27], and miR-210 [28,29] were also
found to be up-regulated in prostate cancer, and miR-31
[30] and miR-145b [20,21,31] and miR-126 [31] were
found to be down-regulated; in our study of Chinese pa-
tients, however, these miRNAs showed no significant
change. The reason for these discrepancies is not clear.
Recently, BoydLk et al. [32] pointed out that prostate can-
cer is a genetic disease characterized by multiple genomic
alterations, including point mutations, microsatellitevariations, and chromosomal alterations such as transloca-
tions, insertions, duplications, and deletions. The study
suggests that the potential effects of the complex nature
and heterogeneity of this disease might lead to miRNAs’
being differentially expressed in different populations.
Among the identified 15 differentially expressed miR-
NAs in Chinese patients, we selected miR-188-5p, miR-
19a, miR-193a-5p, and miR-374b for further study and
found that only miR-374b and miR-19a showed the as-
sociation of miRNA expression with the clinical-
pathological features of PCA patients.
IPA pathway analysis showed that the targets of the
two miRNAs also had a critical role in cellular assembly
and organization, DNA replication, recombination and
Table 3 Prognostic value of miRNA expression for the
biochemical recurrence-free survival in univariate and
multivariate analyses by Cox regression
Hazard ratio(95% CI) P
Univariate
hsa-miR-188-5p 1.02(0.70 -1.48) 0.91
hsa-miR-19a 0.85(0.35 -1.77) 0.66
hsa-miR-193a-5p 0.60(0.35 -1.02) 0.06
hsa-miR-374b 0.61(0.50 -0.75) 0.000**
Gleason score 3.32(2.26-4.87) 0.000**
Preoperative PSA 1.00(1.00-1.01) 0.013*
Pathological tumor stage 3.85(1.59-9.32) 0.003**
Age 1.04(0.98-1.09) 0.19
Clinical stage group 0.85(0.39-1.89) 0.69
Multivariate
hsamiR374b 0.38(0.17 -0.85) 0.018*
Gleason score 2.39(1.34-4.23) 0.003**
Preoperative PSA 1.01(1.00-1.01) 0.022*
Pathological tumor stage 2.17(0.64-7.37) 0.21
* P < 0.05, ** P < 0.01.
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http://www.biomedcentral.com/1471-2164/14/757repair cellular compromise, and the cell cycle. It is of inter-
est that many of the target genes associated with the differ-
entially expressed mRNAs in prostate cancer were found to
be identical to the predicted target genes of differentially
expressed miRNAs, as well as to be related to cancer and
metastasis—e.g. TOP1 [33], RALA [34], SNX18, PNPT1
[35], PARD6B [36], KRAS [37] and HIPK2 [38].
Additionally, Up-regulated expression of miR-19a was
found in lung cancer and colorectal cancer [39-42]. OurFigure 7 Pathway analysis for target genes of miR-374b. The 10 most
multiple datasets, y-axis displays the significance. For the ratio, taller bars havcurrent study firstly reported miR-19a up-regulated
in PCa with clinical-pathological features in Chinese
patients but not in non-Chinese patients. The result
provides a starting point for future research into the
function of miR-19a and suggests that miR-19a up-
regulated may involve heterogeneous disorder of Chinese
patients.
MiR-374b was reported as being involved in multiple
physical functions and diseases, such as adipocyte differ-
entiation [43,44], lipid metabolism, renal Ca2+ homeosta-
sis [45], vascular permeability in injury [46], and lung
cancer [47]. Our results showed that miR-374b is an in-
dependent predictor of shorter biochemical recurrence-
free survival of PCa by in situ hybridization. Interest-
ingly, it was recently reported that miR-374 in seminal
plasma can, as a diagnostic biomarker for male infertil-
ity, combine with other miRNAs [48]. As such, our find-
ings suggest that the further study of the miR-374b
expression level in prostate fluid or serum of prostate
cancer patients may promote the clinical application of
the miR-374b as PCa biomarker.
Conclusions
Our study supports the concept that alternations of
miRNA expression play an important role in prostate
carcinogenesis. miR-23b, miR-220, miR-221, miR-222
and miR-205 maybe common critical therapeutic targets
in the different populations. However, while a miRNA
potentially has hundreds of target genes, relatively few
targets have been experimentally validated. Our inte-
grated analysis for mRNA microarray and miRNA
microarray will help us to investigate the effect ofsignificant canonical pathways across the entire dataset, and across
e more genes associated with the canonical pathway than shorter bars.
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http://www.biomedcentral.com/1471-2164/14/757specifically inhibiting/enhancing the function of miRNAs
on the activity of their putative target genes, gene trans-
lation and the various stages of cancer development.
This study also identifies those 15 specific expressed
miRNAs in Chinese patients. The clinical feature statis-
tics reveal that only miR-374b and miR-19a have signifi-
cant correlation with clinic-pathological features, which
suggest miR-374b and miR-19a may be involved in pros-
tate cancer progression of Chinese patients.Additional files
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